Overview

Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.

Status:
RECRUITING

Trial end date:
2028-04-01

Target enrollment:

Participant gender:

Summary

This is a phase II single-arm study of low-dose pembrolizumab (100mg, fixed-dose) plus chemotherapy in women aged 18 years or older with histologically confirmed persistent, recurrent, or metastatic cervical cancer who are ineligible for curative-intent treatment (surgery and/or radiation therapy) and who have not been previously treated with systemic chemotherapy, with the exception of chemotherapeutic agents used as radiosensitizers (cisplatin or carboplatin concurrent with radiation therapy).

Phase:

PHASE2

Details

Lead Sponsor:

Instituto Nacional de Cancer, Brazil

Treatments:

Carboplatin
Cisplatin
Drug Therapy
Paclitaxel
pembrolizumab